Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments.
beta-interferon
disability progression
early treatment
glatiramer acetate
multiple sclerosis
observational studies
propensity score
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
26 May 2022
26 May 2022
Historique:
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
27
5
2022
Statut:
aheadofprint
Résumé
Therapeutic management of relapsing-remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression among RRMS first-line treated patients. This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1996/01/01 to 2012/31/12 (N=5,279) from ten MS expert OFSEP centers (Observatoire Français de la Sclérose en Plaques). The delay from treatment start to attain an irreversible Expanded Disability Status Scale score of 3.0 were compared between "Early" group (N= 1,882; treated within 12 months following MS clinical onset) and "Later" group using propensity score weighted Kaplan-Meier methods, overall and stratified by age. Overall, the restricted mean time before reaching EDSS 3.0 (RMST) from treatment start was 11 years and two months for patients treated within the year following MS clinical onset and 10 years and seven months for patients treated later. Thus, early treated patients gained 7 months (95% CI: [4-11] months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in RMST was respectively six months (95% CI: [1-10] months) and 14 months (95% CI: [4-24] months) in the "≤40 years" age group and in the ">40 years" age group, in favour of early group. . Early treatment initiation resulted in a significant reduction of disability progression among patients with RRMS, and also among older patients.
Sections du résumé
BACKGROUND
BACKGROUND
Therapeutic management of relapsing-remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression among RRMS first-line treated patients.
METHODS
METHODS
This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1996/01/01 to 2012/31/12 (N=5,279) from ten MS expert OFSEP centers (Observatoire Français de la Sclérose en Plaques). The delay from treatment start to attain an irreversible Expanded Disability Status Scale score of 3.0 were compared between "Early" group (N= 1,882; treated within 12 months following MS clinical onset) and "Later" group using propensity score weighted Kaplan-Meier methods, overall and stratified by age.
RESULTS
RESULTS
Overall, the restricted mean time before reaching EDSS 3.0 (RMST) from treatment start was 11 years and two months for patients treated within the year following MS clinical onset and 10 years and seven months for patients treated later. Thus, early treated patients gained 7 months (95% CI: [4-11] months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in RMST was respectively six months (95% CI: [1-10] months) and 14 months (95% CI: [4-24] months) in the "≤40 years" age group and in the ">40 years" age group, in favour of early group. .
CONCLUSIONS
CONCLUSIONS
Early treatment initiation resulted in a significant reduction of disability progression among patients with RRMS, and also among older patients.
Identifiants
pubmed: 35617144
doi: 10.1111/ene.15422
pmc: PMC9544933
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Romain Casey
(R)
François Cotton
(F)
Jérôme De Sèze
(J)
Pascal Douek
(P)
Francis Guillemin
(F)
David Laplaud
(D)
Christine Lebrun-Frenay
(C)
Alexandre Pachot
(A)
Thibault Moreau
(T)
Javier Olaiz
(J)
Jean Pelletier
(J)
Claire Rigaud-Bully
(C)
Bruno Stankoff
(B)
Sandra Vukusic
(S)
Hélène Zephir
(H)
Romain Marignier
(R)
Marc Debouverie
(M)
Gilles Edan
(G)
Jonathan Ciron
(J)
Aurélie Ruet
(A)
Nicolas Collongues
(N)
Catherine Lubetzki
(C)
Hélène Zephir
(H)
Pierre Labauge
(P)
Gilles Defer
(G)
Mikaël Cohen
(M)
Agnès Fromont
(A)
Sandrine Wiertlewsky
(S)
Eric Berger
(E)
Pierre Clavelou
(P)
Bertrand Audoin
(B)
Claire Giannesini
(C)
Olivier Gout
(O)
Eric Thouvenot
(E)
Olivier Heinzlef
(O)
Abdullatif Al-Khedr
(A)
Bertrand Bourre
(B)
Olivier Casez
(O)
Philippe Cabre
(P)
Alexis Montcuquet
(A)
Abir Wahab
(A)
Jean-Philippe Camdessanché
(JP)
Serge Bakchine
(S)
Aude Maurousset
(A)
Haifa Ben Nasr
(H)
Karolina Hankiewicz
(K)
Corinne Pottier
(C)
Nicolas Maubeuge
(N)
Céline Labeyrie
(C)
Chantal Nifle
(C)
Informations de copyright
This article is protected by copyright. All rights reserved.
Références
Eur J Neurol. 2008 Sep;15(9):916-21
pubmed: 18637953
J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):671-6
pubmed: 1527537
J Neurol. 2018 Mar;265(3):701-707
pubmed: 29392457
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
J Neurol. 2020 Feb;267(2):308-316
pubmed: 30610426
Lancet Neurol. 2009 Nov;8(11):987-97
pubmed: 19748319
Eur J Neurol. 2018 Oct;25(10):1262-e110
pubmed: 29847005
Brain. 2020 Sep 1;143(9):2637-2652
pubmed: 32710096
BMC Med Res Methodol. 2015 Mar 21;15:25
pubmed: 25888416
Mult Scler. 2015 Apr;21(4):433-41
pubmed: 25257611
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Eur J Neurol. 2022 May 26;:
pubmed: 35617144
Am J Med. 2020 Feb;133(2):178-181
pubmed: 31618617
Neurology. 2016 Sep 06;87(10):978-87
pubmed: 27511182
Stat Med. 2016 Dec 30;35(30):5642-5655
pubmed: 27549016
Mult Scler. 2020 Jan;26(1):118-122
pubmed: 30541380
J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11
pubmed: 19200870
Biom J. 2019 Sep;61(5):1270-1289
pubmed: 30306605
Mult Scler. 2013 Jul;19(8):1074-83
pubmed: 23234810
Am J Epidemiol. 2006 Jun 15;163(12):1149-56
pubmed: 16624967
Autoimmun Rev. 2017 Jun;16(6):658-665
pubmed: 28428119
Ann Neurol. 2009 Oct;66(4):513-20
pubmed: 19847899
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1179
pubmed: 24706944
J Clin Oncol. 1991 Jan;9(1):191-2
pubmed: 1985169
Stat Med. 2007 Feb 20;26(4):734-53
pubmed: 16708349
Mult Scler. 2017 Aug;23(9):1233-1240
pubmed: 27754943
Mult Scler Relat Disord. 2014 Mar;3(2):147-55
pubmed: 25878002
Biometrics. 2016 Mar;72(1):215-21
pubmed: 26302239
Comput Methods Programs Biomed. 2004 Jul;75(1):45-9
pubmed: 15158046
Mult Scler. 2021 Oct;27(11):1760-1770
pubmed: 33403937
Brain. 2010 Jul;133(Pt 7):1900-13
pubmed: 20423930
Mult Scler. 2018 Feb;24(2):96-120
pubmed: 29353550
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9
pubmed: 24218527
Mult Scler Relat Disord. 2017 Oct;17:75-83
pubmed: 29055479